JP7097880B2 - Ｍａｌｔ１分解のための化合物 - Google Patents

Ｍａｌｔ１分解のための化合物 Download PDF

Info

Publication number
JP7097880B2
JP7097880B2 JP2019523739A JP2019523739A JP7097880B2 JP 7097880 B2 JP7097880 B2 JP 7097880B2 JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019523739 A JP2019523739 A JP 2019523739A JP 7097880 B2 JP7097880 B2 JP 7097880B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019523739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537599A5 (enExample
JP2019537599A (ja
Inventor
メルニック，アリ，エム．
ギャバス，ロレーナ，フォンタン
アス，イルカイ
キャサレーナ，ガブリエラ
グレイ，ナタナエル，エス．
スコット，デイビッド，エー．
ハッチャー，ジョン
デュ，グァンユェン
ウー，ハオ
ヂァオ，ヂー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Cornell University
Original Assignee
Boston Childrens Hospital
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Cornell University filed Critical Boston Childrens Hospital
Publication of JP2019537599A publication Critical patent/JP2019537599A/ja
Publication of JP2019537599A5 publication Critical patent/JP2019537599A5/ja
Application granted granted Critical
Publication of JP7097880B2 publication Critical patent/JP7097880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019523739A 2016-11-01 2017-10-31 Ｍａｌｔ１分解のための化合物 Active JP7097880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416066P 2016-11-01 2016-11-01
US62/416,066 2016-11-01
PCT/US2017/059234 WO2018085247A1 (en) 2016-11-01 2017-10-31 Compounds for malt1 degradation

Publications (3)

Publication Number Publication Date
JP2019537599A JP2019537599A (ja) 2019-12-26
JP2019537599A5 JP2019537599A5 (enExample) 2020-12-10
JP7097880B2 true JP7097880B2 (ja) 2022-07-08

Family

ID=62077048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523739A Active JP7097880B2 (ja) 2016-11-01 2017-10-31 Ｍａｌｔ１分解のための化合物

Country Status (4)

Country Link
US (1) US10689366B2 (enExample)
EP (1) EP3535254A4 (enExample)
JP (1) JP7097880B2 (enExample)
WO (1) WO2018085247A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341007B1 (en) 2015-08-28 2020-12-23 Cornell University Malt1 inhibitors and uses thereof
CN108473499B (zh) * 2015-11-13 2021-07-23 诺华股份有限公司 新颖的吡唑并嘧啶衍生物
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3731848A4 (en) 2017-12-28 2021-12-15 The General Hospital Corporation TARGETING OF THE CBM-SIGNALOSOME COMPLEX FOR INDUCING REGULATORY T-CELLS TO CITIZE INFLAMMATION OF THE TUMOR MICRO-ENVIRONMENT
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3904350B1 (en) 2018-04-12 2023-08-23 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
MY206796A (en) 2018-04-23 2025-01-08 Celgene Corp Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
UA127065C2 (uk) 2018-04-25 2023-03-29 Баєр Акціенгезельшафт Нові гетероарил-триазольні та гетероарил-тетразольні сполуки як пестициди
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CN110615779B (zh) * 2018-06-20 2023-03-24 上海科技大学 制备来那度胺衍生物的方法
MY209902A (en) * 2018-11-28 2025-08-09 Takeda Pharmaceuticals Co Heterocyclic compound
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CA3143508A1 (en) * 2019-06-24 2020-12-30 Dana-Farber Cancer Institute, Inc. Hck degraders and uses thereof
MX2022000954A (es) 2019-07-23 2022-02-14 Bayer Ag Novedosos compuestos de heteroaril-triazol como plaguicidas.
TW202128664A (zh) 2019-10-09 2021-08-01 德商拜耳廠股份有限公司 作為除害劑之新穎雜芳基三唑化合物
CA3162364A1 (en) * 2019-12-20 2021-06-24 Gesine Kerstin Veits Protein tyrosine phosphatase degraders and methods of use thereof
PH12022551523A1 (en) * 2019-12-27 2024-01-29 Schra–Dinger Inc Cyclic compounds and methods of using same
US20230312639A1 (en) * 2020-04-23 2023-10-05 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021241611A1 (ja) 2020-05-27 2021-12-02 武田薬品工業株式会社 複素環化合物の製造方法
JP2023530937A (ja) * 2020-06-17 2023-07-20 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｅ３－リガーゼ系の共動員を介した標的化された異常なα－シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
US12123053B2 (en) 2021-01-29 2024-10-22 Eurofins Discoverx Corporation Molecular glue screening assays and methods for practicing same
MX2024008008A (es) 2021-12-30 2024-07-12 Shanghai Hansoh Biomedical Co Ltd Derivado triciclico inhibidor, metodo de preparacion de este y aplicacion de este.
US20250092066A1 (en) * 2022-01-18 2025-03-20 Aurigene Oncology Limited Substituted bicyclic heterocycles as malt-1 inhibitors
WO2023143249A1 (zh) * 2022-01-28 2023-08-03 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
JPWO2023149450A1 (enExample) 2022-02-02 2023-08-10
KR20240163083A (ko) * 2022-02-25 2024-11-18 테지드 테라퓨틱스 인코포레이티드 Malt1의 protac
CN119325475A (zh) 2022-06-06 2025-01-17 C4医药公司 双环取代的戊二酰亚胺cereblon结合剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043347A1 (en) 2003-07-24 2005-02-24 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
WO2012071414A2 (en) 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
WO2015105518A1 (en) 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60036812T2 (de) * 1999-07-07 2008-07-17 Astrazeneca Uk Ltd. Chinazolin derivate
JP5479105B2 (ja) * 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10806737B2 (en) * 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043347A1 (en) 2003-07-24 2005-02-24 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
WO2012071414A2 (en) 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
WO2015105518A1 (en) 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
奥村文彦，Elongin BC型 E3ユビキチンリガーゼと細胞機能制御，生化学，2013年，85(2)，76-88

Also Published As

Publication number Publication date
US10689366B2 (en) 2020-06-23
JP2019537599A (ja) 2019-12-26
US20190263785A1 (en) 2019-08-29
EP3535254A4 (en) 2020-06-24
WO2018085247A1 (en) 2018-05-11
EP3535254A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
JP7097880B2 (ja) Ｍａｌｔ１分解のための化合物
JP7260521B2 (ja) タウタンパク質分解の化合物
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7142022B2 (ja) Ｍａｌｔ１の阻害剤およびそれらの使用
JP6491202B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP2021514958A (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP7427812B2 (ja) 血漿カリクレインの阻害剤およびその使用
JP6989505B2 (ja) Ｍａｌｔ１阻害剤およびその使用
KR20150126670A (ko) Ras 억제제 및 그의 용도
CA2968884A1 (en) Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP2024529487A (ja) Ｒｏｃｋ２阻害剤およびその使用
JP7185631B2 (ja) 抗線維化化合物
JP2021529174A (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
US20230322747A1 (en) Oxadiazole hdac6 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201030

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220628

R150 Certificate of patent or registration of utility model

Ref document number: 7097880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250